About Gilead Sciences
Funding & Growth
✓ Pros
- • Leader in HIV and antiviral therapies
- • Strong financials and cash position
- • Foster City/Bay Area location
- • Excellent compensation and benefits
- • Growing oncology pipeline (Kite)
✗ Cons
- • HIV franchise maturity concerns
- • Some restructuring in recent years
- • Large company processes
- • Competition in key therapeutic areas
🏢 Working Here
Gilead Sciences is headquartered in Foster City, CA (San Francisco Bay Area), with significant computational biology operations in both Bay Area locations and increasingly, Boston-area collaborations for oncology and cell therapy work.
Foster City is home to Gilead's core virology, oncology, and inflammation computational teams.
The company transformed hepatitis C treatment (Harvoni cures), leads in HIV management (Biktarvy, Descovy), and expanded through acquisitions in oncology (Immunomedics for Trodelvy, Kite Pharma for Yescarta CAR-T).
The Bay Area location provides access to UCSF, Stanford, Berkeley for academic collaborations, plus proximity to other Bay Area biotech companies.
Bioinformaticians work across virology (HIV, HBV, emerging pathogens), CAR-T cell therapy (Kite in Santa Monica & Bay Area), and oncology (antibody-drug conjugates).
The culture emphasizes patient impact - HIV/HCV work has saved millions of lives globally - combined with innovation and scientific excellence.
Work involves analyzing viral resistance mutations, CAR-T expansion and toxicity biomarkers, tumor genomics for ADC response, and hepatitis B cure research.
Gilead has exceptional computational infrastructure built over decades of virology focus.
The company increasingly collaborates with Boston-area institutions for oncology and immunology given the concentration of cancer research expertise.
Each coast offers unique advantages - Bay Area for virology heritage and UCSF/Stanford partnerships, Boston collaborations for oncology innovation.
🧬 Bioinformatics Focus
Gilead's computational biology spans virology, cell therapy, and oncology. Key areas:
- HIV and antiviral drug resistance - analyzing viral sequences from patients on therapy, predicting resistance mutations, designing next-generation antivirals that overcome resistance, pharmacogenomic analysis for optimal dosing,
- CAR - T cell therapy (Kite) - analyzing patient samples from Yescarta and Tecartus trials, understanding CAR-T expansion and persistence, predicting cytokine release syndrome and neurotoxicity, optimizing manufacturing,
- Antibody - drug conjugates - analyzing tumor samples from Trodelvy trials in breast cancer, understanding payload delivery and resistance, biomarker development,
- Hepatitis B cure research - analyzing cccDNA dynamics, immune responses, viral integration, developing functional cure strategies,
- NASH and fibrosis - multi-omic analysis of liver disease progression, fibrosis biomarkers. Gilead's virology expertise is world-class with proprietary databases of HIV and HBV sequences from millions of patients globally. The Kite acquisition brought cell therapy computational capabilities. Technical challenges include analyzing rapidly mutating viruses, predicting long-term drug resistance, understanding complex CAR-T biology, and developing biomarkers for novel mechanisms (ADCs, NASH).
📈 Career Growth & Development
Career Paths
Scientist Track
Leadership Track
Compensation
Competitive biotech-level compensation includes 15-20% bonuses and stock grants (GILD). The Bay Area location means high salaries but also a high cost of living.
Development
Gilead supports employee development through training, conferences, and external collaborations. Publications are encouraged, with many scientists publishing in high-impact journals.
Mobility
Internal mobility between therapeutic areas is possible at Gilead.
Culture
The HIV and HCV success stories create strong company pride. Gilead values both virology/oncology expertise and cross-functional impact.
Network
Gilead has an extensive alumni network, particularly in antiviral and cell therapy fields.
Growth
Career growth opportunities are good given the company size and diversifying portfolio. Career stability is generally good given Gilead's strong financial position.
💊 Top Medicines & Blockbuster Drugs
Biktarvy (bictegravir/emtricitabine/tenofovir)
2018Indication: HIV - single-tablet regimen
$13.3B (2024) - World's top HIV therapy, once-daily complete regimen
Trodelvy (sacituzumab govitecan)
2020Indication: Triple-negative breast cancer, metastatic urothelial cancer
$1.2B (2024) - Antibody-drug conjugate, Immunomedics acquisition
Yescarta (axicabtagene ciloleucel)
2017Indication: CAR-T therapy for large B-cell lymphoma, follicular lymphoma
$1.0B (2024) - Kite Pharma acquisition
Descovy (emtricitabine/tenofovir alafenamide)
2016Indication: HIV treatment and PrEP (pre-exposure prophylaxis)
$5.6B (2024) - Improved renal/bone safety vs Truvada
Veklury (remdesivir)
2020Indication: COVID-19 antiviral
$2.8B (2022 peak, declining) - IV treatment, emergency use